Tiong Albert, Rischin Danny, Young Richard J, Herschtal Alan, Solomon Ben, D'Costa Ieta, Fua Tsien, Liu Chen, Coleman Andrew, Kleid Stephen, Dixon Benjamin J, Corry June
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Laryngoscope. 2018 Sep;128(9):2076-2083. doi: 10.1002/lary.27131. Epub 2018 Feb 26.
OBJECTIVES/HYPOTHESIS: The outcomes of unilateral radiotherapy treatment for patients with p16/HPV-positive squamous cell carcinomas of unknown primary (SCCUP) affecting cervical lymph nodes are under-reported. Compared to radiating large volumes of the pharyngeal axis (the more common approach), this is potentially a much less toxic treatment for a good prognosis group.
Retrospective cohort study.
We identified patients with SCCUP who were treated radically at our center and did not have parotid or isolated level IV or V nodal involvement. Failure-free and overall survivals were calculated using Kaplan-Meier methods.
From 2004 to 2012, there were 49 radically treated patients with SCCUP. Fourteen patients had bilateral neck treatment (they had bilateral nodal disease or suspected lesions in the base of tongue, though not proven with biopsy), two had surgery alone, whereas 33 had unilateral radiotherapy (after neck dissection, excisional biopsy, or definitively with concurrent chemotherapy). Of the 33 patients, 21 tested positive to p16/HPV and had median follow-up of 57 months. In this group, no isolated contralateral neck failures or putative primaries emerged. There was 1/21 (4.3%) ipsilateral neck failure, 1/21 (4.3%) concurrent contralateral neck and distant failure, and 1/21 (4.3%) patient with distant failure. The 5-year freedom from failure was 78% (95% confidence interval [CI]: 56%-100%) and overall survival was 90% (95% CI: 79%-100%).
With no emergence of putative primaries and no isolated contralateral neck failures, this single-institution experience in p16/HPV-positive SCCUP patients suggests that unilateral radiotherapy may be an underutilized management strategy.
4 Laryngoscope, 128:2076-2083, 2018.
目的/假设:影响颈部淋巴结的p16/HPV阳性原发灶不明的鳞状细胞癌(SCCUP)患者接受单侧放射治疗的结果报道较少。与照射咽轴的大体积区域(更常用的方法)相比,对于预后良好的患者群体,这可能是一种毒性小得多的治疗方法。
回顾性队列研究。
我们确定了在我们中心接受根治性治疗且没有腮腺或孤立的IV或V级淋巴结受累的SCCUP患者。使用Kaplan-Meier方法计算无失败生存率和总生存率。
2004年至2012年,有49例接受根治性治疗的SCCUP患者。14例患者接受双侧颈部治疗(他们有双侧淋巴结疾病或舌根部疑似病变,尽管活检未证实),2例仅接受手术,而33例接受单侧放射治疗(在颈部清扫、切除活检或明确联合化疗后)。在33例患者中,21例p16/HPV检测呈阳性,中位随访时间为57个月。在该组中,未出现孤立的对侧颈部失败或假定的原发灶。有1/21(4.3%)例同侧颈部失败,1/21(4.3%)例同时出现对侧颈部和远处失败,1/21(4.3%)例患者出现远处失败。5年无失败生存率为78%(95%置信区间[CI]:56%-100%),总生存率为90%(95%CI:79%-100%)。
由于未出现假定的原发灶且没有孤立的对侧颈部失败,该单机构对p16/HPV阳性SCCUP患者的经验表明,单侧放射治疗可能是一种未得到充分利用的管理策略。
4《喉镜》,128:2076 - 2083,2018年。